Tag Archives: ABT

Ratings Alert: Abbott Laboratories (NYSE:ABT) and Deere & Co. (NYSE:DE)

Posted on May 20, 2013 by Thomas Vedder

Deere & Co. (NYSE:DE) rating was downgraded to sell from neutral by Goldman Sachs, and its price target was lowered to $85 as compared to $98 per share in a noted dated May 17. Leading expert Jerry Revich reported Goldman …

Posted in Latest Headlines | Tagged Abbott Laboratories (NYSE:ABT), ABT, DE, Deere & Company (NYSE:DE) | Comments Off

Healthcare Sector Quick Review: Abbott (NYSE:ABT), Quest Diagnostics (NYSE:DGX) – ABT, DGX, LH

Posted on April 18, 2013 by Thomas Vedder

Healthcare sector finished lower on Wednesday’s trading session and sector moved down -0.60%. If we consider key movers of this sector so XOMA Corp (NASDAQ:XOMA) and BioScrip Inc (NASDAQ:BIOS) were major percentage decliners while key percentage gainer was Alkermes Plc …

Posted in Healthcare, Latest Headlines | Tagged Abbott Laboratories, ABT, DGX, Laboratory, LH, NYSE:ABT, NYSE:DGX, NYSE:LH, Quest Diagnostics | Comments Off

Investors Watch List: Dover (NYSE:DOV), Abbott Laboratories (NYSE:ABT) – DOV, ABT

Posted on April 17, 2013 by Thomas Vedder

Dover Corp (NYSE:DOV) on Wednesday announced higher profit in fiscal Q1, more than Wall Street forecasts, mainly assisted by higher revenues on acquisitions. The corporation also backed its fiscal year 2013 earnings and sales growth outlook.

Net earnings for first …

Posted in Latest Headlines | Tagged Abbott Laboratories, ABT, DOV, Dover, NYSE:ABT, NYSE:DOV | Comments Off

SYY, JNJ, ABT, WU, LUV, DAL, SIRI, NWSA, RAD

Posted on February 4, 2013 by Geoff Noir

SYSCO Corporation (NYSE:SYY) reported lower net earnings in the fiscal second-quarter on Monday. It announced earnings of $221.37 million or $0.38 a share, evaluated against $250.11 million or $0.43 a share in previous year.

Food distribution giant announced quarterly adjusted …

Posted in Latest Headlines, Services | Tagged Abbott Laboratories, ABT, DAL, Delta Air Lines, JNJ, Johnson, LUV, NASDAQ:NWSA, NASDAQ:SIRI, NASDAQ:SYY, news, NWSA, NYSE:ABT, NYSE:DAL, NYSE:JNJ, NYSE:LUV, NYSE:RAD, NYSE:WU, RAD, Rite Aid, SIRI, Sirius XM Radio, Southwest Airlines, SYY, SYYle, Western Union, WU | Comments Off

Covidien PLC (NYSE:COV) Superior Sales Masked by Split Off Costs, Outlook Raised – COV, BDX, BCR, BMY, PFE, JNJ, ANTH, ABT, KERX

Posted on January 25, 2013 by Thomas Vedder

Covidien PLC (NYSE:COV) witnessed a 0.2% drop in fiscal first-quarter earnings as costs to divide the health-care products firm weighed over its bubbly sales.

The firm also lifted its fiscal 2013 sales target, now anticipating a 5% to 8% hike, …

Posted in Healthcare, Latest Headlines | Tagged Abbott Laboratories, ABT, ANTH, Anthera Pharmaceuticals, BCR, BDX, Becton, BMY, Bristol-Myers Squibb, C.R. Bard, COV, Covidien, Dickinson, JNJ, Johnson & Johnson, KERX, Keryx Biopharmaceuticals, NASDAQ:ANTH, NASDAQ:KERX, NYSE:ABT, NYSE:BCR, NYSE:BDX, NYSE:BMY, NYSE:COV, NYSE:JNJ, NYSE:PFE, PFE, Pfizer | Comments Off

Bristol Myers Squibb (NYSE:BMY) Fiscal Q4 Profit Outshines Wall Street Forecasts – BMY, PFE, ABT, ABBV, ARIA, BSX, ARNA, AZN, MRK

Posted on January 24, 2013 by Geoff Noir

Bristol Myers Squibb Co (NYSE:BMY) on Thursday announced fiscal Q4 earnings that surpassed analysts’ forecasts after taking a tax benefit for a hepatitis C medicine that failed previous year.

The New York-based drug manufacturer announced in a statement that net …

Posted in Healthcare, Latest Headlines | Tagged Abbott Laboratories, ABBV, AbbVie, ABT, Arena Pharmaceuticals, ARIA, Ariad Pharmaceuticals, ARNA, AstraZeneca, AZN, BMY, Boston Scientific, Bristol-Myers Squibb, BSX, Merck, MRK, NASDAQ:ARIA, NASDAQ:ARNA, NYSE:ABBV, NYSE:ABT, NYSE:AZN, NYSE:BMY, NYSE:BSX, NYSE:MRK, NYSE:PFE, PFE, Pfizer | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.